Hemophagocytic Lymphohistiocytosis Clinical Trial
Official title:
Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis
This study is a multi-site Phase Ib/II, 2-arm non-randomized clinical trial to determine the efficacy and tolerability of a response-adapted regimen combining ruxolitinib, dexamethasone, and etoposide as Frontline therapy for patients with newly diagnosed hemophagocytic lymphohistiocytosis (HLH) or as Salvage therapy for patients with relapsed/refractory HLH. Primary Objective - To determine the efficacy and tolerability of a response-adapted ruxolitinib-containing regimen for patients with newly diagnosed HLH. Secondary Objectives - To describe the efficacy and tolerability of a response-adapted ruxolitinib-containing regimen for patients with relapsed/refractory HLH. - To describe the overall response and outcome for patients with newly diagnosed or relapsed/refractory HLH who are treated with this response-adapted ruxolitinib-containing regimen. Exploratory Objectives - To estimate the pharmacokinetic (PK) parameters of ruxolitinib, assess covariates of ruxolitinib pharmacokinetics, and test whether the drug's effectiveness is correlated with systemic drug exposure. - To query specific immunologic biomarkers and determine whether the levels of these biomarkers correlate with disease response and outcome.
Status | Recruiting |
Enrollment | 62 |
Est. completion date | August 2026 |
Est. primary completion date | August 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Weeks to 22 Years |
Eligibility | Inclusion Criteria: Frontline Arm: 1. Patient is =6 weeks and =22 years of age. 2. Patient weighs =3 kg. 3. Patient is able to take medication PO and/or patient or parent is willing to have NG tube placed if patient is unable to take medications PO. 4. Patient has active HLH if: - Patient has =5 of 8 Diagnostic HLH criteria listed below, OR - Patient has known fHLH (e.g., patient has pathogenic/likely pathogenic germline variant(s) in genes such as PRF1, UNC13D, STX11, STXBP2, LYST, RAB27A, XIAP, SH2D1A, NLCR4) and meets =4 of the diagnostic HLH criteria listed below, OR - Patient has high likelihood of fHLH based on absent perforin, SAP, XIAP expression and meets =4 of the Diagnostic HLH Criteria listed below: - Fever - Splenomegaly (If present at any point prior to starting study drug) - Cytopenias affecting =2 of 3 cell lineages in the peripheral blood (hemoglobin <9 g/dL, platelets <100 × 10^9/L, ANC <1000/mm^3) - Hypertriglyceridemia (fasting triglycerides =265 mg/dL) or hypofibrinogenemia (fibrinogen =150 mg/dL) - Presence of hemophagocytosis in BM or other tissues - Low or absent NK-cell activity (if present at any point prior to starting study drug) OR decreased CD107a mobilization (if present at any point prior to starting study drug) - Ferritin =500 ng/mL - Soluble IL-2 receptor (CD25) =2400 U/mL 5. Patient has not received prior HLH therapy, except steroids (any dose or length of therapy is allowed) OR anakinra (any dose or length of therapy is allowed). 6. Patient, parent, or legal authorized representative (LAR) must provide informed consent. Inclusion Criteria: Salvage Arm: 1. Patient is =6 weeks and =22 years of age. 2. Patient weighs =3 kg. 3. Patient or parent is willing to have the NG tube placed if patient is unable to take medications PO. 4. Patient has past history of HLH, defined as meeting =5 of 8 HLH- 2004 diagnostic criteria for those with no known HLH-associated mutations, OR =4 of 8 HLH-2004 diagnostic criteria for those with known familial disease. 5. Patient must have active HLH at the time of eligibility assessment, defined as 3 or more of the following Relapsed/Refractory HLH Criteria: - Fever - Splenomegaly (recurrent or worsening) - ANC <1000/mm^3 × 2 assessments over at least 3 days OR platelets <100 × 10^9/L × 2 assessments over at least 3 days, OR need for platelet transfusions - Hypofibrinogenemia (fibrinogen =150 mg/dL) - Soluble IL-2 receptor level = 2400 U/mL - Worsening CNS symptoms OR new abnormal brain magnetic resonance imaging (MRI) findings deemed consistent with CNS HLH by the primary treating physician OR CSF cell count =5 mm^3 (with or without hemophagocytosis) OR CSF protein higher than the institutional upper limit of normal OR CSF neopterin higher than the institutional upper limit of normal - Presence of hemophagocytosis in the BM or other tissues - Increasing ferritin × 2 assessments over at least 3 days (both levels must be =2000 ng/mL) 6. Patient must be deemed by the primary treating physician to have not responded to prior therapy by either not having or maintaining a response 7. Patient must have received prior HLH-directed therapy: - At least 2 weeks of steroids (equivalent to at least 5 mg/m^2/day dexamethasone or 1 mg/kg/day methylprednisolone) AND at least 2 doses of etoposide; OR - At least 1 dose of ATG 8. Patient or parent/LAR must provide informed consent. Laboratory findings must be given on at least 2 assessments, each completed at least 1 day apart, EXCEPT CNS radiologic/laboratory findings in which a single abnormal value is sufficient. Exclusion Criteria: Frontline and Salvage Arms: 1. Patient is <6 weeks or >22 years of age. 2. Patient weighs <3 kg. 3. Patient has isolated CNS disease. 4. Life expectancy is <2 weeks. 5. Patient is likely to require <4 weeks of therapy (i.e., HSCT is imminent). 6. Patients with creatinine clearance (CrCl) <15 mL/min who are NOT receiving dialysis. 7. Patient has evidence of severe organ dysfunction, defined as: Severe liver dysfunction (ALT >1000 U/L), OR Cardiorespiratory failure requiring any ionotropic support OR extracorporeal life support, OR high frequency oscillatory ventilation, other forms of respiratory support or ventilation are allowed if the patient is not on vasopressors) 8. Patient with pre-existing rheumatologic disorder. 9. Patient with known active malignancy. 10. Patient with previous HSCT, except when HSCT was for treatment of HLH. 11. Patient is pregnant or lactating. 12. Patients who expect to conceive or father children within the projected duration of the study and/or who are unwilling to use highly effective methods of contraception throughout the duration of the study, starting with the screening visit through the end of the treatment visit. 13. Patient has suspected or known fungal disease. 14. Patient is unable to tolerate administration of drugs PO or NG. 15. Patient is taking rifampin or St. John's Wort. 16. Patient is taking another investigational agent or is enrolled on another treatment protocol. 17. Patient, parent, or LAR are unable or unwilling to provide informed consent. Additional Exclusion Criteria for the Frontline Arm: 1. Patient has or is receiving treatment with a JAK inhibitor (including ruxolitinib), ATG, alemtuzumab, etoposide, tocilizumab, emapalumab or any other HLH-directed therapy other than steroids or anakinra (as defined in the Frontline Arm Inclusion Criteria, #5). Additional Exclusion Criteria for the Salvage Arm: 1. Patient has or is receiving treatment with a JAK inhibitor (including ruxolitinib) or alemtuzumab within the last 3 months. 2. Patient has received therapy on the Frontline Arm of this trial. |
Country | Name | City | State |
---|---|---|---|
United States | John Hopkins University | Baltimore | Maryland |
United States | Dana-Farber Cancer Institute | Boston | Massachusetts |
United States | Levine Children's Hospital | Charlotte | North Carolina |
United States | University of Texas Southwestern Medical Center | Dallas | Texas |
United States | Texas Children's Hospital | Houston | Texas |
United States | St. Jude Children's Research Hospital | Memphis | Tennessee |
United States | Children's Wisconsin/Medical College of Wisconsin | Milwaukee | Wisconsin |
United States | Cohen Children's Medical Center | New Hyde Park | New York |
United States | Children's Hospital of Orange County | Orange | California |
United States | Children's Hospital of Philadelphia | Philadelphia | Pennsylvania |
United States | Phoenix Children's Hospital | Phoenix | Arizona |
United States | University of California San Francisco | San Francisco | California |
United States | Children's National Medical Center | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
St. Jude Children's Research Hospital | Cures Within Reach, Incyte Corporation, North American Consortium for Histiocytosis |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Complete Response (CR)/Complete Response with Incomplete Hematologic Recovery (CRi) | Will be reported as number and percentage of patients meeting CR/CRi criteria at the end of 8 weeks of therapy | 8 weeks | |
Primary | Adverse events (AEs) associated with the ruxolitinib-containing regimen | Cumulative incidence will be estimated by the Kalbfleisch-Prentice method for severe toxicities that lead to morbidity and mortality. | up to 8 weeks | |
Primary | Adverse events (AEs) associated with the ruxolitinib-containing regimen | Cumulative incidence will be estimated by the Kalbfleisch-Prentice method for severe toxicities that lead to morbidity and mortality. | up to 1 year after diagnosis | |
Secondary | Overall Response (CR/CRi plus Partial Response [PR])) | Will be reported as number and percentage/proportion of patients meeting response (CR/CRi plus PR) criteria at the end of 8 weeks of therapy | 8 weeks | |
Secondary | Survival to eight weeks | The proportion (probability) of patients surviving to the end of 8 weeks will be estimated by sample proportions along with the 95% exact binomial CIs in the Frontline and Salvage Arms, respectively. | 8 weeks | |
Secondary | Survival to allogeneic hematopoietic stem cell transplantation (HSCT) in patients for whom an allogeneic HSCT is planned | The proportion (probability) of surviving to HSCT will be estimated by sample proportions along with 95% exact binomial CIs in the Frontline and Salvage Arms, respectively. | up to 1 year | |
Secondary | Survival to one year after initiation of the treatment protocol | One-year Overall Survival (OS) rate will be estimated in all patients | 1 year after initiation of treatment | |
Secondary | Survival one year after HSCT | One-year post-HSCT Overall Survival (OS) rate will be estimated in patients who receive transplantation, in the Frontline and Salvage Arms, respectively. | 1 year post HSCT | |
Secondary | Time to Response (CR/CRi or PR) | The mean time to CR/PR including CRi for week 8 response evaluation (will be estimated by the sample mean along with 95% CIs, in the Frontline and Salvage Arms, respectively. The median time will be estimated by the sample median along with the 95% finite- sample CI. | At weeks 2, 4, 6, and 8 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01652092 -
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
|
N/A | |
Recruiting |
NCT02912702 -
L-DEP as an Initial Treatment for EBV-HLH
|
Phase 3 | |
Terminated |
NCT00176826 -
T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06038422 -
GTP Regimen in the Treatment of Refractory/Recurrent HLH
|
Phase 3 | |
Completed |
NCT03510650 -
Diagnostic Biomarkers for Adult Hemophagocytic Lymphohistiocytosis in Critically Ill Patients (HEMICU)
|
||
Completed |
NCT03259230 -
Study to Evaluate Interferon Gamma (IFNγ) and Other Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH)
|
||
Active, not recruiting |
NCT01494103 -
Administration of Donor T Cells With the Caspase-9 Suicide Gene
|
Phase 1 | |
Recruiting |
NCT05164978 -
DEP Combine With PD-1 Antibody as an Treatment for EBV-HLH
|
N/A | |
Recruiting |
NCT01821781 -
Immune Disorder HSCT Protocol
|
Phase 2 | |
Terminated |
NCT01547143 -
Pilot Study of Etoposide-based Therapy and Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis
|
N/A | |
Active, not recruiting |
NCT00006056 -
Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders
|
N/A | |
Terminated |
NCT00006054 -
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
|
N/A | |
Recruiting |
NCT03795909 -
Ruxolitinib Combined With Dexamethasone for HLH
|
Phase 1/Phase 2 | |
Recruiting |
NCT03533790 -
DEP-Ru Regimen as a Salvage Therapy for HLH
|
Phase 3 | |
Not yet recruiting |
NCT05315336 -
L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH
|
Phase 3 | |
Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
Recruiting |
NCT04326348 -
A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis(HLH)
|
Phase 1 | |
Recruiting |
NCT05546060 -
Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLH
|
Phase 1 | |
Recruiting |
NCT05137522 -
Chidamide Combines With VP-16 and Methylprednisolone in the Treatment of HLH
|
N/A | |
Recruiting |
NCT04120090 -
Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis
|
Phase 3 |